Theoretical evaluation of supersaturation of amorphous solid dispersion formulations with different drug/polymer combinations using mathematical modeling-Reference-Cited by-同舟云学术

Theoretical evaluation of supersaturation of amorphous solid dispersion formulations with different drug/polymer combinations using mathematical modeling

Published:2022-09 Issue: Volume:625 Page:122110
ISSN:0378-5173
Container-title:International Journal of Pharmaceutics
language:en
Short-container-title:International Journal of Pharmaceutics

Author:

Hirai Daiki,Tsunematsu Hiroki,Kimura Shin-ichiro,Itai Shigeru,Fukami Toshiro,Iwao Yasunori

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference28 articles.

1. An investigation into the dissolution properties of celecoxib melt extrudates: understanding the role of polymer type and concentration in stabilizing supersaturated drug concentrations;Abu-Diak;Mol. Pharm.,2011

2. Understanding the behavior of amorphous pharmaceutical systems during dissolution;Alonzo;Pharm. Res.,2010

3. Solubility advantage of amorphous drugs and pharmaceutical cocrystals;Babu;Cryst. Growth Des.,2011

4. Investigation and correlation of physical stability, dissolution behaviour and interaction parameter of amorphous solid dispersions of telmisartan: a drug development perspective;Dukeck;Eur. J. Pharm. Sci.,2013

5. Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: True supersaturation vs. apparent solubility enhancement;Frank;Int. J. Pharm.,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of the Influence of Copovidone Properties and Hot-Melt Extrusion Process on Level of Impurities, In Vitro Release, and Stability of an Amorphous Solid Dispersion Product;Molecular Pharmaceutics;2024-09-12

2. Curcumin amorphous solid dispersions benefit from hydroxypropyl methylcellulose E50 to perform enhanced anti-inflammatory effects;International Journal of Biological Macromolecules;2023-12

3. Application of Sucrose Acetate Isobutyrate in Development of Co-Amorphous Formulations of Tacrolimus for Bioavailability Enhancement;Pharmaceutics;2023-05-09